No Result
View All Result
No Result
View All Result
No Result
View All Result

Taurine | Ingredient Overview: Pharmacokinetics, Formulations, Human Research Evidence, Safety, and Combinations

by SHIZAM Editorial Team
May 29, 2026

Taurine is a sulfur-containing amino sulfonic acid found naturally in human tissues and animal-derived foods, and human research has examined it mainly in cardiovascular, metabolic, exercise, and selected neurological contexts. (Review)

Taurine is not a protein-building amino acid and is not pharmacologically equivalent to caffeine; it is a small sulfur-containing compound involved in cell-volume regulation, membrane stability, bile-acid chemistry, mitochondrial function, and cellular stress responses. Human evidence is most developed for Cardiovascular Health, Diabetes and Glycemic Control, Obesity and Weight Regulation, and exercise-related Muscle Health, although trial designs, durations, and populations vary substantially. (Review) (Review) The overall evidence is more mature for cardiometabolic markers than for mental-health, neurological, or broad performance outcomes. (Review)

Ingredient Identity

  • Official name(s): Taurine; 2-aminoethanesulfonic acid. (Review)
  • Synonyms: Taurine, aminoethanesulfonic acid. (Review)
  • Classification: Sulfur-containing amino sulfonic acid; it is not incorporated into proteins as a proteinogenic amino acid. (Review)
  • CAS number: 107-35-7.
  • Endogenous vs exogenous: Taurine is present in human tissues and can also be obtained from dietary sources, particularly animal-derived foods. (Review)

Ingredient Snapshot

  • Classification: Taurine is a sulfur-containing amino sulfonic acid involved in cell-volume regulation, membrane stability, bile-acid conjugation, mitochondrial function, and redox-related physiology. (Review)
  • Endogenous vs exogenous status: Taurine is both endogenous, meaning present in the body, and exogenous, meaning it can also be supplied through diet or isolated oral formulations. (Review)
  • Primary human research domains: Human studies have examined blood pressure, heart failure, glucose and lipid markers, obesity-related biomarkers, exercise performance, and selected psychiatric or neurological conditions. (Review) (Review)
  • Common study formats: Taurine has been studied in randomized controlled trials, crossover trials, dietary-exposure studies, pharmacokinetic studies, and systematic reviews. (Research) (Review)
  • Pharmacokinetic characterization status: Human oral pharmacokinetic data are available, including a single 4 g oral dose study, but the evidence does not establish one general time-to-peak or half-life applicable across all doses, populations, and formulations. (Research)
  • Regulatory context (U.S./EU): In the United States, FDA issued a response letter for a Generally Recognized as Safe notice for specified taurine food uses, while clarifying that FDA had not made its own safety determination. (FDA) In Europe, EFSA has evaluated taurine in energy-drink ingredient and caffeine-interaction contexts. (EFSA) (EFSA)
  • Evidence maturity: The human evidence is most developed for cardiometabolic outcomes and less mature for neurological, psychiatric, and broad exercise-performance outcomes. (Review)

Introduction

Taurine is a small sulfur-containing compound that occurs naturally in human tissues and in foods such as meat, seafood, and dairy. It is often described as conditionally essential in some nutrition contexts, meaning that endogenous synthesis may be insufficient under particular physiological, developmental, or clinical conditions. (Review)

Taurine is frequently discussed because it appears in energy drinks, sports-nutrition formulations, infant-nutrition research, and cardiometabolic studies. Human research has examined taurine in blood pressure, heart failure, diabetes-related markers, obesity-related inflammation, exercise performance, and selected neurological or psychiatric research settings. (Review) (Review)

This article is informational only, describes taurine as a biochemical substance studied in human research, and does not provide medical or dosing advice.

Quick Summary

  • Taurine is a sulfur-containing amino sulfonic acid naturally present in the body and in animal-derived foods, and it has been studied as both a dietary compound and an isolated oral research ingredient. (Review)
  • The most developed human evidence concerns Cardiovascular Health and cardiometabolic markers, including blood pressure, heart failure, glucose-related markers, and lipids. (Review) (Review)
  • A randomized prehypertension trial studied 1.6 g/day for 12 weeks and reported lower blood pressure and improved vascular-function measures. (Research)
  • Diabetes-related evidence is mixed: some trials reported improvements in glycemic or oxidative-stress markers, while another trial reported no clear effect on insulin sensitivity or blood lipids. (Research) (Research)
  • Exercise findings are protocol-dependent; one acute athlete study reported improved anaerobic power, while another triathlete study reported no clear benefit for performance or muscle-damage markers. (Research) (Research)
  • Human studies have primarily used oral taurine, and the available evidence does not strongly characterize extended-release, sublingual, transdermal, or injectable formulations. (Research)
  • Taurine’s regulatory status depends on use context; FDA has responded to a food-use safety notice, and EFSA has evaluated taurine in energy-drink-related safety assessments. (FDA) (EFSA)

Human Research Findings by Condition

Cardiovascular Health

Human research on Cardiovascular Health is one of the more developed evidence areas for taurine. Studies include a randomized trial in prehypertension and several small heart-failure trials, while systematic reviews describe potential cardiometabolic signals alongside limitations from study size, duration, and heterogeneity. (Review) (Review)

Key human study

Dose studied: 1.6 g/day
Population: Adults with prehypertension
Duration: 12 weeks

A randomized, double-blind, placebo-controlled trial examined taurine supplementation in adults with prehypertension. The study reported lower clinic and ambulatory blood pressure and improved vascular-function measures after taurine supplementation. (Research)

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Additional human study

Dose studied: 500 mg three times daily
Population: Patients with heart failure
Duration: 2 weeks

A randomized heart-failure study examined oral taurine before and after incremental exercise testing. The trial reported changes in inflammatory and atherogenic markers, although the short duration and disease-specific population limit generalization beyond the study context. (Research)

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Diabetes and Glycemic Control

Human research on Diabetes and Glycemic Control has produced mixed findings. Some type 2 diabetes studies reported favorable changes in glucose-related, lipid, oxidative-stress, or glycation-related markers, while another trial in metabolically at-risk men reported no clear insulin or lipid effect. (Review) (Research)

Key human study

Dose studied: 3 g/day
Population: People with type 2 diabetes
Duration: 8 weeks

A clinical trial examined taurine supplementation in people with type 2 diabetes and measured glycemic-control and lipid-profile outcomes. The study reported favorable changes in several markers, but the broader diabetes evidence remains limited by short duration and variation across study designs. (Research)

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 1.5 g/day
Population: Overweight men with genetic predisposition to type 2 diabetes
Duration: 8 weeks

A randomized human trial tested taurine for insulin secretion, insulin action, and serum lipids in overweight men with genetic risk for type 2 diabetes. The study reported no clear effect on the main insulin-related or lipid outcomes. (Research)

Result: Human clinical study reported no clear effect
Evidence strength: Mixed
Study source: (Research)

Obesity and Weight Regulation

Human studies in Obesity and Weight Regulation have mainly evaluated biomarkers rather than long-term body-weight outcomes. Trials in women with obesity have studied taurine in relation to inflammation, oxidative-stress markers, adiponectin, lipids, and body-composition-related measures. (Research) (Research)

Key human study

Dose studied: 3 g/day
Population: Women with obesity
Duration: 8 weeks

A double-blind placebo-controlled study reported that taurine increased plasma taurine and adiponectin in women with obesity. The study also reported reductions in hs-CRP and TBARS, which are research markers commonly used to assess inflammation and oxidative stress. (Research)

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 3 g/day with a weight-loss diet
Population: Women with obesity
Duration: 8 weeks

A randomized clinical trial studied taurine as part of a weight-loss diet intervention. Because taurine was combined with dietary intervention, the study is best interpreted as combined-intervention evidence rather than isolated taurine evidence. (Research)

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Muscle Health

Human Muscle Health research has evaluated taurine in exercise performance and recovery contexts. Results vary because studies differ in athlete type, dose timing, performance test, training status, and whether the primary outcome is performance, soreness, muscle damage, or metabolic response. (Review) (Review)

Key human study

Dose studied: 6 g single dose
Population: Elite male speed skaters
Duration: Acute crossover testing

A double-blind randomized placebo-controlled crossover study tested a single taurine dose before anaerobic power assessment. The study reported improved anaerobic-power outcomes, but the finding comes from a specific athletic population and an acute performance protocol. (Research)

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Emerging
Study source: (Research)

Additional human study

Dose studied: Not clearly summarized in the verified report
Population: Triathletes
Duration: Exercise-performance study context

A randomized study in triathletes reported no clear benefit on performance or muscle-damage markers. This neutral finding indicates that taurine’s exercise-related effects are not consistent across sport types and protocols. (Research)

Result: Human clinical study reported no clear effect
Evidence strength: Mixed
Study source: (Research)

Mental Health

Human Mental Health evidence for taurine remains exploratory. The main verified human source is a phase 2 randomized placebo-controlled trial that studied taurine as an adjunctive intervention in first-episode psychosis rather than as a general intervention for mood, anxiety, or cognition. (Research)

Key human study

Dose studied: 4 g/day
Population: People with first-episode psychosis taking low-dose antipsychotic medication
Duration: 12 weeks

A phase 2 randomized placebo-controlled trial studied taurine as an adjunct to antipsychotic medication in first-episode psychosis. The study is relevant to psychiatric clinical research, but it does not establish taurine as a stand-alone mental-health intervention. (Research)

Result: Human clinical studies reported mixed findings
Evidence strength: Emerging
Study source: (Research)

Neurological Health

Human Neurological Health evidence is limited and condition-specific. The verified human evidence includes a rare-disease clinical trial in succinic semialdehyde dehydrogenase deficiency, while broader neurological interpretations rely more on biological plausibility than on clinical confirmation. (Research) (Review)

Key human study

Dose studied: Not clearly summarized in the verified report
Population: People with succinic semialdehyde dehydrogenase deficiency
Duration: Clinical trial context

A human trial studied taurine in succinic semialdehyde dehydrogenase deficiency and reported no significant improvement in adaptive behavior. This finding is relevant to rare-disease research, but it does not establish broader neurological effects. (Research)

Result: Human clinical study reported no clear effect
Evidence strength: Inconclusive
Study source: (Research)

Dosage & Study Snapshot (Research Context)

Human taurine studies span ordinary dietary exposure, diet-pattern biomarker studies, clinical nutrition contexts, oral supplementation trials, and single-dose pharmacokinetic or performance studies. Ordinary dietary taurine exposure is generally measured in milligrams per day, whereas many intervention trials used gram-level oral doses. These exposure ranges describe human research contexts and should not be interpreted as dosing guidance.

Food intake context: approximately 9–400 mg/person/day:

Regulatory materials summarized estimated ordinary omnivorous dietary taurine intake at approximately 9–400 mg/person/day. This range provides dietary exposure context and helps distinguish food-derived taurine intake from the gram-level exposures used in many clinical trials. (FDA)

Result: Observational association
Evidence strength: Observational
Notes / limitations: This is an exposure estimate, not an intervention trial.

Diet-pattern exposure: vegans, vegetarians, and omnivores:

Diet-pattern studies measured taurine-related markers in plasma, urine, diet, and breast milk across vegan, vegetarian, and omnivore groups. These studies suggest that avoidance of animal-derived foods is associated with lower taurine-related biomarkers, but they do not establish a supplement dose or clinical effect. (Research) (Research)

Result: Observational association
Evidence strength: Observational
Notes / limitations: These studies characterize taurine exposure and status rather than clinical efficacy.

1.5 g/day oral taurine:

A trial in overweight men with genetic risk for type 2 diabetes studied 1.5 g/day for 8 weeks and reported no clear effect on insulin secretion, insulin action, or serum lipids. A heart-failure trial used the same total daily amount as 500 mg three times daily and reported changes in inflammatory and atherogenic markers in a different clinical population. (Research) (Research)

Result: Mixed findings
Evidence strength: Limited
Notes / limitations: Similar total daily exposure was studied in different populations with different outcome measures.

1.6 g/day oral taurine:

A 12-week randomized trial in adults with prehypertension studied 1.6 g/day. The study reported lower blood pressure and improved vascular-function measures, making it one of the clearer human trials in taurine-related cardiometabolic research. (Research)

Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: The study population had prehypertension, so interpretation should remain specific to that research context.

3 g/day oral taurine:

Several metabolic studies used 3 g/day for 8 weeks. This exposure has been studied in type 2 diabetes and obesity-related research, with outcomes including glucose, lipids, adiponectin, inflammation, oxidative-stress markers, and body-composition-related measures. (Research) (Research)

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: Findings differ by population, baseline metabolic status, and selected outcome.

4 g single oral dose:

A human pharmacokinetic study used a 4 g single oral dose in fasting healthy male volunteers. This study is useful for understanding how oral taurine appears in blood over time, but it was not designed to test clinical efficacy. (Research)

Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Pharmacokinetic evidence describes exposure, not clinical benefit.

4 g/day adjunctive psychiatric research dose:

A phase 2 trial studied 4 g/day for 12 weeks as adjunctive taurine in first-episode psychosis. This dose belongs to a specialized psychiatric research context and does not establish general effects on mood, stress, focus, or cognition. (Research)

Result: Mixed findings
Evidence strength: Emerging
Notes / limitations: Taurine was studied as adjunctive therapy, not as a stand-alone psychiatric intervention.

6 g single acute exercise dose:

A double-blind randomized crossover study tested a 6 g single dose in elite male speed skaters. The study reported improved anaerobic-power outcomes, but the finding is specific to acute testing in trained athletes. (Research)

Result: Statistically significant improvement
Evidence strength: Emerging
Notes / limitations: Acute athlete data may not generalize to non-athlete populations or long-term outcomes.

Key Takeaways from Human Research

  • Taurine has the most developed human evidence in cardiometabolic research, especially blood pressure, heart failure, glucose-related markers, and lipid-related markers. (Review) (Review)
  • The clearest blood-pressure trial studied 1.6 g/day for 12 weeks in adults with prehypertension and reported improved blood pressure and vascular-function outcomes. (Research)
  • Diabetes-related evidence is not uniform; some studies reported favorable metabolic-marker changes, while another trial reported no clear effect on insulin sensitivity or serum lipids. (Research) (Research)
  • Exercise research is protocol-dependent, with positive findings in one acute anaerobic athlete study and neutral results in a triathlete study. (Research) (Research)
  • Taurine safety and regulatory evidence should be interpreted by use context; food-use safety notices and energy-drink assessments do not establish clinical efficacy. (FDA) (EFSA)

Origin & Natural Occurrence

Taurine occurs naturally in human tissues and is also supplied by diet, especially animal-derived foods. It is considered conditionally essential in some contexts because endogenous synthesis can be insufficient under particular developmental, nutritional, or clinical conditions. (Review)

Diet-pattern studies support the relationship between food pattern and taurine status. Studies comparing vegan, vegetarian, and omnivore groups found differences in taurine-related plasma and urine measures, consistent with taurine’s presence in animal-derived foods. (Research) (Research)

Manufactured taurine used as an added food or supplement ingredient is typically supplied as isolated taurine rather than as a whole-food matrix. FDA’s submitted Generally Recognized as Safe notice materials address taurine as an added ingredient under specified intended-use conditions. (FDA)

How It Behaves in the Body

Taurine participates in several basic physiological processes that help cells maintain stability under changing conditions. It is involved in cell-volume regulation, membrane stabilization, redox balance, ion movement, bile-acid conjugation, and mitochondrial-related biology. (Review)

Cell-volume regulation refers to the ability of cells to maintain appropriate internal fluid balance. Taurine is also discussed in relation to membrane stability and ion-channel physiology, which are important for maintaining cellular electrical and structural function. (Review)

Taurine participates in bile-acid conjugation, a process that helps bile acids support fat digestion and absorption. This biochemical role is one reason taurine appears in infant-nutrition and clinical-nutrition discussions. (Review)

Taurine has also been studied in relation to mitochondria, the cellular structures involved in energy metabolism. Mechanistic reviews describe taurine’s relationship to mitochondrial function and mitochondrial-stress models, but mechanistic evidence should not be interpreted as proof of clinical benefit without supportive human outcome data. (Review)

The strongest conclusion is that taurine has multiple established biochemical roles in human physiology. The more conservative clinical conclusion is that changing taurine exposure does not produce consistent measurable effects across every human outcome area studied. (Review) (Review)

Absorption & Delivery Formats

Oral immediate-release: Oral taurine is the main format represented in the verified human evidence. Clinical trials have used oral daily taurine in gram-level amounts, and a pharmacokinetic study used a single 4 g oral dose in fasting healthy male volunteers. (Research) (Research)

Oral extended-release: Direct human evidence comparing extended-release taurine with standard oral taurine is limited in the verified evidence base. Extended-release taurine should not be assumed to have the same pharmacokinetic profile as immediate oral taurine unless formulation-specific human data are available. (Research)

Sublingual: Direct human absorption evidence for sublingual taurine is limited in the verified evidence base. Most human findings should therefore be interpreted as oral taurine evidence rather than sublingual evidence. (Research)

Transdermal: Direct human evidence for transdermal taurine delivery is limited in the verified evidence base. Claims about transdermal taurine require delivery-specific human pharmacokinetic evidence. (Research)

Injectable / IV: Taurine has been discussed in specialized parenteral-nutrition contexts, but that setting differs from routine oral supplementation. One study examined serum and urinary taurine in long-term parenteral nutrition patients, which is a clinical nutrition context rather than a general delivery-format comparison. (Research)

Quick Facts at a Glance

Onset (reported): Taurine has been studied acutely in exercise research, including a single-dose trial in elite speed skaters. This shows that some outcomes have been measured after acute exposure, but it does not establish a universal onset time across cardiovascular, metabolic, neurological, or psychiatric outcomes. (Research)

Time to peak (Tmax): A human pharmacokinetic study measured blood taurine after a 4 g oral dose in fasting healthy male volunteers. The verified evidence supports that oral taurine has been pharmacokinetically studied, but it does not support a single general Tmax statement across all taurine formulations, doses, and populations. (Research)

Half-life (t½): The verified evidence does not support one simple half-life value that can be generalized across taurine dose, diet status, population, and formulation. Half-life interpretation should remain tied to specific pharmacokinetic study conditions rather than presented as a universal property of all taurine exposure. (Research)

Typical duration: Human taurine studies range from acute single-dose testing to multi-week clinical trials. Examples include 2-week heart-failure research, 8-week metabolic and obesity studies, and 12-week prehypertension or psychiatric research. (Research) (Research)

Absorption routes studied: The most relevant human evidence concerns oral taurine from foods or supplementation. Parenteral-nutrition research exists in specialized clinical settings, but it should not be interpreted as evidence for ordinary non-oral taurine formats. (Research) (Research)

Formulation differences: Most verified human studies used oral taurine and did not compare multiple commercial delivery formats. Current evidence is insufficient to rank immediate-release, extended-release, sublingual, transdermal, or injectable formulations. (Research)

Variability drivers: Taurine exposure can vary by diet pattern, as vegan and vegetarian comparison studies show differences in taurine-related biomarkers. Response may also vary by baseline health status, clinical condition, dose, duration, and selected outcome. (Research) (Review)

Tolerance / adaptation: Human studies do not establish a clear tolerance or adaptation pattern for taurine. Several trials lasted 8–12 weeks, but they were not primarily designed to test whether taurine effects diminish, accumulate, or adapt over time. (Research) (Research)

Evidence strength snapshot: Taurine has moderate human evidence for some cardiometabolic markers and limited or mixed evidence for many other outcomes. Confidence is limited by differences in dose, duration, participant characteristics, and outcome selection across trials. (Review) (Review)

Safety, Interactions & Regulation

Human taurine studies include short-term and multi-week trials in heart failure, prehypertension, diabetes, obesity, exercise, and psychiatric research contexts. A systematic review of taurine in heart failure reported no significant safety concerns across included studies, but that conclusion applies to the reviewed heart-failure literature rather than every possible taurine exposure or population. (Review)

The most common interaction question concerns taurine with caffeine because both can appear in energy drinks. EFSA’s caffeine safety opinion stated that common energy-drink constituents, including taurine, were unlikely to adversely interact with caffeine at the exposure levels reviewed. (EFSA)

Population-specific interpretation is important because taurine studies often enroll defined groups, such as adults with prehypertension, patients with heart failure, people with type 2 diabetes, women with obesity, or athletes. Results from these groups should not be automatically generalized to children, pregnant individuals, people with complex medical conditions, or people taking medication. (Research) (Research)

In the United States, FDA issued a response letter for a Generally Recognized as Safe notice, often abbreviated GRAS, for taurine under specified intended food-use conditions. FDA stated that it had no questions regarding the notifier’s GRAS conclusion, while also clarifying that FDA had not made its own GRAS determination. (FDA)

FDA’s GRAS Notice 000586 PDF contains the notifier’s submitted safety and intended-use dossier for taurine in enhanced water beverages. This is a food-ingredient safety context and does not indicate FDA approval of taurine for treating, preventing, or curing disease. (FDA)

In Europe, EFSA adopted a scientific opinion on taurine and D-glucurono-gamma-lactone as ingredients commonly used in some energy drinks. EFSA also discussed taurine in its caffeine safety-opinion context when evaluating common energy-drink constituents and potential interactions. (EFSA) (EFSA)

Evidence Overview

The human evidence for taurine is most coherent when interpreted by outcome area. The strongest evidence cluster concerns cardiometabolic research, including blood pressure, heart failure, glucose-related markers, lipids, inflammation, and obesity-related biomarkers. Evidence is less settled for exercise performance, Mental Health, and Neurological Health, where studies are more specialized, mixed, or limited. (Review) (Review)

A prehypertension trial using 1.6 g/day for 12 weeks is one of the clearest individual human findings because it measured blood pressure and vascular function in a randomized placebo-controlled design. Heart-failure research includes multiple small trials and systematic-review evidence, but the studies differ in dose, duration, and clinical endpoints. (Research) (Review)

Diabetes-related findings are mixed. Some type 2 diabetes studies reported changes in glycemic, lipid, oxidative-stress, or glycation-related markers, while a trial in overweight men with genetic predisposition to type 2 diabetes reported no clear effect on insulin secretion, insulin action, or serum lipids. (Research) (Research)

Obesity-related studies have reported changes in biomarkers such as adiponectin, hs-CRP, TBARS, lipids, and body-composition-related measures. However, some studies were short and included diet intervention, which makes it difficult to isolate taurine-specific effects. (Research) (Research)

Exercise research is heterogeneous. Reviews and trials suggest possible effects in some endurance or anaerobic-performance settings, but neutral findings in triathletes and differences in protocol limit broad conclusions. (Review) (Research)

Mental-health and neurological evidence should be interpreted cautiously. A phase 2 trial studied adjunctive taurine in first-episode psychosis, while a neurological rare-disease trial reported no significant improvement in adaptive behavior, so these areas remain emerging or inconclusive. (Research) (Research)

Evidence Confidence Classification

The overall human evidence for taurine is Moderate for cardiometabolic markers and Limited / Mixed across broader health claims, because multiple human trials exist but many are short, small, population-specific, or inconsistent. (Review) (Review)

This classification is strongest for Cardiovascular Health and cardiometabolic outcomes, where randomized trials and systematic reviews are available. (Research) (Review)

The classification is lower for Mental Health, Neurological Health, and broad Muscle Health outcomes because the evidence is more specialized, mixed, or protocol-dependent. (Research) (Review)

Mechanistic evidence helps explain why taurine is biologically important, but mechanisms alone do not establish consistent clinical outcomes in humans. (Review)

Similar Ingredients & Comparators

Similar supplement-style ingredients:

  • Glycine
  • L-carnitine
  • Magnesium
  • Coenzyme Q10
  • L-arginine
  • Citrulline
  • N-acetylcysteine
  • Creatine
  • Beta-alanine
  • Omega-3 fatty acids

Medical / pharma comparator categories:

  • Antihypertensive medication categories
  • Heart-failure medication categories
  • Glucose-lowering medication categories
  • Lipid-lowering medication categories
  • Anti-inflammatory medication categories
  • Psychiatric adjunctive-therapy categories

Combination Context

Taurine + Caffeine:

Taurine is commonly discussed with caffeine because both can appear in energy drinks. EFSA’s caffeine safety opinion stated that common energy-drink constituents, including taurine, were unlikely to adversely interact with caffeine at the exposure levels reviewed. (EFSA)

Taurine + D-glucurono-gamma-lactone:

EFSA evaluated taurine together with D-glucurono-gamma-lactone because both are common ingredients in some energy drinks. This evidence is mainly relevant to safety assessment of ingredient co-presence, not to a proven benefit from combining them. (EFSA)

Taurine + weight-loss diet context:

A randomized clinical trial studied taurine alongside a weight-loss diet in women with obesity. Because the study included both taurine and diet intervention, it is best interpreted as combined-intervention research rather than isolated taurine evidence. (Research)

FAQ

What is taurine?

Taurine is a sulfur-containing amino sulfonic acid found naturally in human tissues and animal-derived foods. It is not a protein-building amino acid and is not pharmacologically equivalent to caffeine. Taurine participates in cell-volume regulation, membrane stability, bile-acid chemistry, and cellular stress-response systems. (Review) (Review)

What does human research study taurine for?

Human research mainly studies taurine for Cardiovascular Health, Diabetes and Glycemic Control, Obesity and Weight Regulation, Muscle Health, and selected Mental Health or Neurological Health contexts. Cardiometabolic studies examine outcomes such as blood pressure, heart failure markers, glucose-related markers, lipids, inflammation, and oxidative-stress markers. Exercise studies examine outcomes such as endurance, anaerobic power, soreness, and muscle-damage markers. (Review) (Review)

What are the best-supported uses?

The best-supported taurine research area is cardiometabolic health, especially blood pressure and related metabolic markers. A prehypertension trial reported improved blood pressure and vascular-function measures with 1.6 g/day for 12 weeks, and systematic reviews have summarized broader cardiometabolic trial evidence. This does not establish taurine as a treatment for cardiovascular disease; it indicates that cardiometabolic research is the most developed human evidence area. (Research) (Review)

Where is evidence mixed or limited?

Evidence is mixed or limited for diabetes, obesity, exercise performance, mental health, and neurological outcomes. Some diabetes and obesity studies reported favorable biomarker changes, but another insulin-sensitivity trial reported no clear effect, and exercise studies vary by sport, dose, and outcome. Mental-health and neurological studies are mostly specialized and do not support broad general conclusions. (Research) (Research) (Research)

How quickly does taurine act?

Taurine has been studied in acute settings, meaning some studies measure outcomes after a single oral dose. For example, a 6 g single-dose athlete study measured anaerobic-power outcomes during acute testing. This does not establish a universal onset time, because blood pressure, metabolic markers, and psychiatric outcomes were studied in multi-week trial designs. (Research) (Research)

What affects absorption and variability?

Taurine exposure and response can vary by diet, dose, formulation, fasting state, baseline health status, and outcome type. Vegan and vegetarian comparison studies suggest that diet pattern can affect taurine-related plasma and urine measures. Clinical trials also differ in population, duration, and outcome selection, which contributes to inconsistent findings. (Research) (Research) (Review)

Is tolerance reported?

A clear tolerance pattern has not been established in the verified human taurine evidence. Some studies lasted 8–12 weeks, but they generally measured blood pressure, metabolic markers, inflammation, or clinical outcomes rather than tolerance development. The available evidence does not support a specific tolerance timeline. (Research) (Research)

Why do taurine studies disagree?

Taurine studies disagree because they examine different populations, doses, durations, and outcome measures. Some trials study clinical populations, others study athletes or metabolic-risk groups, and some combine taurine with another intervention such as dietary change. Reviews of cardiometabolic and exercise research note heterogeneity, which limits confidence in broad conclusions. (Review) (Review)

What ingredients is taurine commonly combined with and why?

Taurine is commonly discussed with caffeine and D-glucurono-gamma-lactone because these ingredients can occur together in energy drinks. EFSA evaluated taurine in energy-drink ingredient contexts and also discussed taurine in caffeine-interaction assessment. This evidence is mainly about safety assessment of combined ingredient exposure, not proof that the combination improves health outcomes. (EFSA) (EFSA)

What foods naturally contain taurine?

Taurine is naturally found mainly in animal-derived foods. FDA’s food-use materials summarize ordinary omnivorous dietary taurine exposure, and human diet-pattern studies show differences in taurine-related biomarkers between vegan, vegetarian, and omnivore groups. These studies support the relationship between dietary pattern and taurine exposure, but they do not establish that supplemental taurine is necessary. (FDA) (Research)

How is taurine regulated?

In the United States, taurine has been the subject of a FDA Generally Recognized as Safe notice response for specified food-use conditions. “Generally Recognized as Safe” is a food-ingredient safety concept for intended uses, not an approval of taurine as a treatment for medical conditions. In Europe, EFSA has evaluated taurine in the context of energy-drink ingredients and caffeine interaction assessment. (FDA) (EFSA)

Resources

More from the Supplement Ingredients & Medical Ingredients Encyclopedia​

No Result
View All Result

© 2026 SHIZAM Limited. All rights reserved.